Abstract:Jian-Jun Xi, 1, &ast Yu Cao, 1, &ast Ruo-Yu He, 1 Jian-Kang Zhang, 2 Yan-Mei Zhao, 1 Qiao Tong, 1 Jian-Feng Bao, 1 Yi-Chen Dong, 3 Rang-Xiao Zhuang, 1 Jin-Song Huang, 1 Yongping Chen, 4 Shou-Rong Liu 1 1 Department of Pharmacy, Hangzhou Xixi Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou, People's Republic of China; 2 School of Medicine, Zhejiang University City College, Hangzhou, People's Republic of China; 3 Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, People's Republic of China; 4 Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Hepatology Institute of Wenzhou Medical University, Wenzhou Key Laboratory of Hepatology, Wenzou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yongping Chen, Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Key Laboratory of Hepatology, Hepatology Institute of Wenzhou Medical University, Wenzhou, Zhejiang Province, 325025, People's Republic of China, Email Shou-Rong Liu, Department of Infectious Diseases, Hangzhou Xixi Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310023, People's Republic of China, Email Objective: Silibinin, a natural product extracted from the seeds of the Silybum marianum , is versatile with various pharmacological effects. However, its clinical application was strongly hampered by its low bioavailability and poor water solubility. Herein, a series of glycosylated silibinin derivatives were identified as novel anti-tumor agents. Materials and Methods: The cell viability was evaluated by CCK8 assay. Furthermore, cell apoptosis and cell cycle progression were tested by flow cytometry. In addition, the pharmacokinetic assessment of compound 15 and silibinin through intravenous administration (i.v., 2 mg/kg) to ICR mice were performed. Results: The synthesized compounds showed better water solubilities than silibinin. Among them, compound 15 exhibited inhibitory activity against DU145 cells with IC 50 value of 1.37 ± 0.140 μ M. Moreover, it arrested cell cycle at G2/M phase and induced apoptosis in DU145 cells. Additionally, compound 15 also displayed longer half-life (T 1/2 = 128.3 min) in liver microsomes than that of silibinin (T 1/2 = 82.5 min) and appropriate pharmacokinetic parameters in mice. Conclusion: Overall, glycosylation of silibinin would be a valid strategy for the development of silibinin derivatives as anti-tumor agents. Graphical Keywords: glycosylation, silibinin derivatives, solubility, anti-proliferative activity Graphical Silymarin is a representative extract derived from the seeds of milk thistle ( Silybum marianum ), which consists of several flavonoid lignin-like compounds (silibinin, isosilybin and silychristin) (Figure 1). 1–4 Silibinin, the most abundant active ingredient of silymarin, exhibits a variety of characteristics in terms of therapeutic activities, including antioxidant, free radicals scavenging, maintaining the stability of cell membrane, promoting hepatocyte proliferation and reducing blood lipids. 5,6 Several animal studies in vivo have confirmed that silibinin possesses a significant inhibitory effect on different types of tumors including liver, colon, prostate, bladder and tongue through the suppression of receptor tyrosine kinase (RTK) represented by epidermal growth factor receptor (EGFR) and insulin-like growth factor 1 receptor (IGF-1R) and the activation of downstream signaling molecules. 7–9 Additionally, enhanced efficacy of chemotherapy drugs can be achieved through combination with silibinin, avoiding the appearance of multidrug resistance (MDR). 10 Figure 1 Chemical structures of respective components of silymarin. Despite a widespread use of silibinin for the treatment of various liver ailments for more than 3 decades, the pharmacological properties of silibinin are considerably hampered by its poor water solubility. 11–14 Numerous approaches have been developed to overcome the low bioavailability of silibinin by means of the structural modification, delivery strategies and so on. 15,16 On the one hand, silibinin derivatives can be obtained by the etherification, oxidation and esterification of hydroxyl groups of silibinin, formation of salts or the co -Abstract Truncated-

Fabrication, characterization and bioevaluation of silibinin loaded chitosan nanoparticles

Fabrication, characterization and in vitro evaluation of silibinin nanoparticles: an attempt to enhance its oral bioavailability

Preparation, characterisation and biological evaluation of biopolymer-coated multi-walled carbon nanotubes for sustained-delivery of silibinin

A Supersaturating Delivery System of Silibinin Exhibiting High Payload Achieved by Amorphous Nano-Complexation with Chitosan.

Solid Lipid Nanoparticles and Chitosan-coated Solid Lipid Nanoparticles as Promising Tool for Silybin Delivery: Formulation, Characterization, and In vitro Evaluation

Effect of silibinin-loaded nano-niosomal coated with trimethyl chitosan on miRNAs expression in 2D and 3D models of T47D breast cancer cell line

Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin.

Synthesis, Characterization, and In-Vitro Evaluation of Silibinin-loaded PEGylated Niosomal Nanoparticles: Potential Anti-Cancer Effects on SW480 Colon Cancer Cells

Preparation of modified chitosan - Amino acid nanoparticles

Delivery of Silybin Using a Zein-Pullulan Nanocomplex: Fabrication, Characterization, in Vitro Release Properties and Antioxidant Capacity

Silibinin-Loaded Amphiphilic PLGA–Poloxamer Nanoparticles: Physicochemical Characterization, Release Kinetics, and Bioactivity Evaluation in Lung Cancer Cells

Alginate/Gelatin scaffolds incorporated with Silibinin-loaded Chitosan nanoparticles for bone formation in vitro

Silibinin-loaded chitosan-capped silver nanoparticles exhibit potent antimicrobial, antibiofilm, and anti-inflammatory activity against drug-resistant nosocomial pathogens

Comparative studies of silibinin contained solid lipid nanoparticles prepared by two methods

Silibinin-Loaded Liposomes: The Influence of Modifications on Physicochemical Characteristics, Stability, and Bioactivity Associated with Dermal Application

Preparation of chelidonine highly loaded poly(lactide-co-glycolide)-based nanoparticles using a single emulsion method: Cytotoxic effect on MDA-MB-231 cell line

Design, Synthesis and Biological Evaluation of Glycosylated Derivatives of Silibinin as Potential Anti-Tumor Agents

Preparation of Silymarin–quercetin Loaded Nanoparticles by Spontaneous Emulsification Solvent Diffusion Method Using D-alpha-tocopheryl Poly (Ethylene Glycol) 1000 Succinate

Silibinin Schiff Base Derivatives Counteract CCl4-Induced Acute Liver Injury by Enhancing Anti-Inflammatory and Antiapoptotic Bioactivities

Formulation and Characterization of Silibinin Entrapped Nano-Liquid Crystals for Activity against Aβ1-42 Neurotoxicity in In-Vivo Model

Phytosomes as a Plausible Nano-Delivery System for Enhanced Oral Bioavailability and Improved Hepatoprotective Activity of Silymarin